Novartis gains positive CHMP opinion for Rasitrio
In Phase III data, Rasitrio demonstrated significantly greater blood pressure reductions compared to dual combinations of each of its individual components
28-Sep-2011 -
Novartis announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Rasitrio® for the treatment of high blood pressure.Rasitrio has been recommended as replacement therapy in patients whose blood pressure is adequately ...
amlodipine
high blood pressure
hypertension
+1